Despite national recommendations, PrEP remains underutilized in many clinical settings because clinicians often lack confidence, time, and practical workflows to consistently identify candidates and act on eligibility findings. Routine care frequently omits a structured sexual health history and assessment, leading …
Despite advances in the prevention and management of atherosclerotic cardiovascular disease (ASCVD), gaps remain in real-world risk assessment and lipid-lowering treatment, particularly among intermediate- and high-risk patients. Inconsistent use of risk assessment tools, variable evaluation of risk-enhancing factors, and suboptimal …
Alzheimer’s disease (AD) is an escalating public health challenge, with rising prevalence and profound burdens on patients, caregivers, and healthcare systems. Recent approvals of amyloid-targeting therapies (ATTs) represent a major advancement in disease-modifying treatment for early symptomatic AD. However, translating …
Alzheimer’s disease (AD) continues to impose a growing public health burden as prevalence rises alongside an aging population. Despite advancements in diagnostic tools and the emergence of Alzheimer’s-targeted therapies (ATTs), many healthcare professionals (HCPs) face challenges in integrating new evidence …
Alzheimer’s disease (AD) remains a leading cause of cognitive decline and functional impairment in older adults, with early diagnosis and intervention offering the greatest opportunity to preserve quality of life. The emergence of novel disease-modifying, amyloid-targeting therapies (ATTs) has created …
As HER2-low and ultralow classifications reshape metastatic breast cancer (mBC) treatment pathways, many practices still face real-world barriers to accurate testing and timely reporting. Intra-laboratory variability, limited uptake of emerging assays, and fragmented communication across care teams can all lead …
Alzheimer’s disease (AD) affects more than 55 million individuals worldwide, leading to progressive decline in memory, cognition, and ability to perform activities of daily living (ADLs). Recent advancements in amyloid-targeting therapies (ATTs) have created new opportunities to alter disease progression …
Health care professionals involved in lupus nephritis (LN) care face challenges in recognizing early signs of renal involvement in systemic lupus erythematosus, navigating an increasingly expanding treatment landscape, and addressing persistent disparities affecting Black and Latine patients. Missed or delayed …
Health care professionals (HCPs) managing lupus nephritis (LN) face persistent gaps in equitable care, with disproportionate burden and worse outcomes among Black and Latine patients driven by structural barriers, delayed recognition, and inconsistent access to specialty services. Despite updated guidelines …